Redefining how the world approaches, prevents, and heals mental health disorders.
We are a biopharmaceutical company that leverages a decentralized platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients.
LEARN MORE
For everyone, everywhere
OUR PERSPECTIVE
Shortcomings of existing therapies
Current standard of care treatments are ineffective for millions worldwide.
Significant burden
Affected People
Global population with mental health disorders
Of US population impacted
Expected that more than half of US population will have a mental health disorder at some point in their lifetime
Global economic impact
Estimated global economic costs of mental health disorders by 2030
Recent impact of COVID-19
Percentage of US adults experiencing symptoms of depression and anxiety rose from 11% in 2019 to 42% end of 2020
Urgent need for innovation
Respond inadequately
A third of patients with depression respond inadequately or relapse with current treatments within certain indications
Slow onset of treatment effect
Frontline treatments for depression and anxiety have slow onset (4-12w)
Relapse rate
Most of the patients treated for opioid use disorder (OUD) relapse
Psychiatry approvals since 2015
Only 17 new drugs approved by the FDA for psychiatry disorders since 2015 – less than 20% relative to oncology (N=107)
Our unique approach
Compounds with prior evidence in humans
To minimize development risk, we focus on compounds that have previously been used in humans and have established safety profiles.
Enabling platform technologies
Decentralized drug development
In addition to funding, our evolving companies have access to our deep domain expertise and operational backbone.
Learn more about our approach
OUR PROGRAMSWHERE WE’RE HEADED
Our technologies drive efficient drug discovery and improved treatment outcomes.
Our unique model combines funding with operational expertise to develop innovative and impactful CNS therapeutics.
OUR PROGRAMSNews & Insights
Articles
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
RL-007: First patient dosed in the Phase 2b study of RL-007 in Cognitive Impairment Associated with Schizophrenia. GRX-917: Presented PD…
Articles
atai Life Sciences to Participate in Upcoming May Investor Conference
NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to…
Articles
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
– Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines NEW…